Ritonavir: An Extraordinary Example of Conformational Polymorphism

@article{Bauer2004RitonavirAE,
  title={Ritonavir: An Extraordinary Example of Conformational Polymorphism},
  author={John Bauer and S. Spanton and R. Henry and J. Quick and W. Dziki and W. Porter and J. Morris},
  journal={Pharmaceutical Research},
  year={2004},
  volume={18},
  pages={859-866}
}
  • John Bauer, S. Spanton, +4 authors J. Morris
  • Published 2004
  • Medicine, Chemistry
  • Pharmaceutical Research
  • AbstractPurpose. In the summer of 1998, Norvir semi-solid capsules supplies were threatened as a result of a new much less soluble crystal form of ritonavir. This report provides characterization of the two polymorphs and the structures and hydrogen bonding network for each form. Methods. Ritonavir polymorphism was investigated using solid state spectroscopy and microscopy techniques including solid state NMR, Near Infrared Spectroscopy, powder X-ray Diffraction and Single crystal X-ray. A… CONTINUE READING
    656 Citations
    Conformational Energy Landscape of the Ritonavir Molecule.
    • 5
    Elucidation of crystal form diversity of the HIV protease inhibitor ritonavir by high-throughput crystallization
    • 170
    • PDF
    Rotigotine: Unexpected Polymorphism with Predictable Overall Monotropic Behavior.
    • 24
    New polymorphs of an old drug: conformational and synthon polymorphism of 5-nitrofurazone.
    • 19
    • PDF
    Crystal Forms of Anti-HIV Drugs: Role of Recrystallization
    • 2
    • PDF

    References

    SHOWING 1-10 OF 22 REFERENCES
    Sulfathiazole polymorphism studied by magic-angle spinning NMR.
    • 76
    Pharmaceutical applications of polymorphism.
    • 690
    Crystal forms of piroxicam pivalate: preparation and characterization of two polymorphs.
    • 19
    Solubility behavior of lamivudine crystal forms in recrystallization solvents.
    • 45
    Polymorphism and drug availability. Solubility relationships in the methylprednisolone system.
    • 96
    On the polymorphism of pharmaceuticals and other molecular crystals. I
    • 613
    A novel, picomolar inhibitor of human immunodeficiency virus type 1 protease.
    • 56